Boston Scientific Corporation 🇺🇸
BSX • Technology • USA
⚡ 96.1/100
Wide Moat Score™
$46.84
+0.0% (24H)
Fundamental Snapshot • Market Cap: $67.9B
PEG Ratio
1.89x
EXPANDED
Forward P/E
14.2x
GROWTH FAIR
Revenue Growth YoY
+7.5%
MODERATE
Gross Margin
69.2%
HIGH PRICING POWER
Free Cash Flow
$2.5B
CASH FORTRESS
Debt / EBITDA
2.2x
LEVERAGED
📊 Proprietary 12-Point Fundamental Audit
| Audit Dimension | Benchmark Criterion | BSX Actual | Evaluation |
|---|---|---|---|
| 1. Economic Moat Strength | Software lock-in / high switching barrier / patent moat | Moat Score 96.1/100 | ✅ WIDE MOAT |
| 2. Pricing Power & Margins | Gross Margin > 40% sustainable | 69.2% Gross Margin | ✅ PASSED |
| 3. Revenue Acceleration | YoY Top-Line Growth > 15% | +7.5% YoY | ⚠️ IN-LINE |
| 4. Peter Lynch PEG Ratio | PEG < 1.2x (Growth at a Reasonable Price) | 1.89x PEG Ratio | ⚠️ ELEVATED |
| 5. Fortress Balance Sheet | Debt / EBITDA < 2.5x | 2.2x Net Leverage | ⚠️ WATCH |
| 6. Free Cash Flow Generation | Positive and compounding FCF | $2.5B Free Cash Flow | ✅ PASSED |
| 7. Multiple vs Sector Median | Forward P/E reasonable vs earnings growth | Forward P/E: 14.2x | ✅ ATTRACTIVE MULTIPLE |
| 8. Management & Insider Ownership | Insider Ownership > 3% | 0.3% Insider Equity | ℹ️ INSTITUTIONAL |
| 9. Superinvestor Whale Backing | Held by Top 25 13F Wall St Whales | Institutional Superinvestor Interest | ℹ️ SCREENED |
| 10. Secular Industry Tailwinds | Exposure to multi-year compound themes | Technology sector expansion | ✅ PASSED |
| 11. Trailing P/E Multiple | Historical earnings multiple sanity | Trailing P/E: 19.0x | ✅ PASSED |
| 12. Overall Moat Conviction | Composite algorithmic evaluation | Overall Score: 96.1/100 | ✅ HIGH CONVICTION |
📝 MoatPicks Investment Thesis
Competitive Moat Breakdown: Innovative cardiovascular and endoscopic surgical devices.
Valuation Verdict: Trading at a Forward P/E of 14.2x and PEG ratio of 1.89x, Boston Scientific Corporation satisfies core fundamental screens for quality and durability.